Natera to Announce Earnings for Previous Quarter on Tuesday, November 8

Trending News 🌥️

Natera Inc Intrinsic Value – Natera Inc ($NASDAQ:NTRA). is a biotechnology company that develops, manufactures, and markets diagnostic products. Natera will announce its earnings for the previous quarter on Tuesday, November 8, according to Zacks.

Earnings

In its most recent earnings report for FY2022 Q2, the company earned 723.5 million USD in total revenue and lost 575.6 million USD in net income. Compared to the previous year, this represents a 15.7% increase in total revenue. Natera Inc.’s total revenue has reached from 391.0 million USD to 723.5 million USD in the last 3 years.

Stock Price

The company’s stock prices have been volatile in recent days, opening at $46.5 on Wednesday and closing at $45.4, down 2.6% from the prior closing price of $46.7. Despite the recent dip, NATERA INC remains one of the most promising companies in the market, with a strong focus on innovative genetic testing and a promising future outlook.

VI Analysis – Natera Inc Intrinsic Value

NATERA INC is a biotechnology company with a focus on genetic testing. The company’s fundamentals reflect its long term potential. The fair value of NATERA INC shares is around $93.1, calculated by VI Line. Now NATERA INC stock is traded at $45.4, undervalued by 51%.

VI Peers

The company’s products are used for pregnancy and fertility testing, as well as for cancer and inherited disease risk assessment. Natera’s competitors include Genetic Technologies Ltd, Dr Lalchandani Labs Ltd, and NeoGenomics Inc.

– Genetic Technologies Ltd ($ASX:GTG)

Genetic Technologies Ltd is a biotechnology company that develops and commercializes molecular diagnostic tests. The company has a market cap of 27.7M as of 2022 and a Return on Equity of -24.9%. The company’s products are used for the detection of genetic disorders and cancer.

– Dr Lalchandani Labs Ltd ($BSE:541299)

Lalchandani Labs Ltd is a pharmaceutical company with a market cap of 141.91M as of 2022. The company has a Return on Equity of 12.87%. The company manufactures and sells pharmaceutical products and services. It offers products and services in the areas of diagnostics, therapeutics, and general health care. The company also provides services in the areas of research and development, manufacturing, marketing, and sales.

– NeoGenomics Inc ($NASDAQ:NEO)

NeoGenomics, Inc. is a holding company, which engages in the business of providing cancer-focused genetic testing services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment includes tumor tissue tests, fluid tests, and other ancillary tests. The Pharma Services segment provides genomic services to pharmaceutical clients to support their drug development programs. The company was founded by Douglas M. Ross in 2001 and is headquartered in Fort Myers, FL.

Summary

NATERA INC will be announcing its earnings results for the previous quarter on Tuesday, November. NATERA INC has been the subject of several research reports. Zacks Investment Research upgraded NATERA INC from a “sell” rating to a “hold” rating in a research report on Wednesday, October. Finally, ValuEngine cut NATERA INC from a “hold” rating to a “sell” rating in a research report on Friday, September. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The disclosure for this sale can be found here. Institutional investors and hedge funds have recently bought and sold shares of the company.

NATERA INC Company Profile Natera, Inc is a diagnostics company. The Company focuses on developing genetic tests to help patients and clinicians manage reproductive health and cancer care throughout the patient journey from preconception to delivery and cancer surveillance. It offers Panorama Non-Invasive Prenatal Test , Horizon Carrier Screening , Spectrum Preimplantation Genetic Diagnosis , Anora Fertility Test and Prolaris prostate cancer test. Receive News & Ratings for NATERA INC Daily. Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for NATERA INC and related companies with MarketBeat.com’s FREE daily email newsletter.